Ignite Creation Date:
2024-05-06 @ 7:32 AM
Last Modification Date:
2024-10-26 @ 11:50 AM
Study NCT ID:
NCT02559492
Status:
TERMINATED
Last Update Posted:
2019-09-25
First Post:
2015-09-23
Brief Title:
Itacitinib Combined With INCB024360 andor Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Study Overview
Official Title:
A Platform Study Exploring the Safety Tolerability Effect on the Tumor Microenvironment and Efficacy of INCB Combinations in Advanced Solid Tumors
Status:
TERMINATED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label Phase 1b platform study in subjects with advanced or metastatic solid tumors The study will be divided into 3 parts Part 1a Part 1b and Part 2 Part 1a will evaluate a JAK inhibitor with JAK1 selectivity Itacitinib in combination with an IDO1 inhibitor epacadostat INCB024360 Group A and Itacitinib in combination with a PI3K-delta inhibitor INCB050465 Group B to determine the MTD or PAD and the recommended Part 1b doses for each combination Once the recommended dose has been identified for each treatment group in Part 1a subjects with advanced solid tumors will be enrolled into expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent Part 1b In Part 2 additional expansion cohorts will be enrolled to further evaluate lower doses of itacitinib and INCB050465 in subjects with select tumor types
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None